Survodutide Once Weekly for the Treatment of Adults with Obesity.

Once-weekly survodutide significantly reduces body weight by approximately 12-13% in adults with obesity without diabetes, outperforming placebo in a phase 3 trial.

• Why it matters: Obesity treatments with GLP-1 receptor agonists have improved management but still leave unmet needs for more effective options. Developing dual agonists like survodutide could address these gaps and enhance weight loss outcomes.
• What they did: The trial involved 725 adults with obesity, randomly assigned to receive survodutide at 3.6 mg or 6.0 mg doses or placebo, alongside lifestyle counseling, with primary endpoints measuring percent weight change and at least 5% weight loss at 76 weeks.
• The result: Survodutide achieved a mean weight reduction of around 12-13%, with over 70% of participants losing at least 5%, demonstrating its potential as a potent obesity treatment and enabling further development of dual receptor agonists.